7Baggers
Quarterly
Annual
    Unit: USD2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 
      
    		          
      cash flows from operating activities:
    		          
      net income
    		-34,505,000 -10,002,000 -29,519,000 -28,044,000 -26,989,000 -26,647,000 -26,697,000 -19,088,000 -18,479,000 -20,974,000 
      adjustments to reconcile net income to net cash from operating activities:
    		          
      depreciation and amortization
    		740,000 1,579,000 617,000 589,000 506,000 450,000 358,000 308,000 273,000 260,000 
      gain on disposal of fixed assets
    		0 0 0 -34,000       
      non-cash consideration for licensing and collaboration revenue
    		0 0   0 0 -77,000 -128,000   
      change in fair value of equity securities
    		9,000 4,000 -22,000 15,000 60,000 -31,000 16,000 88,000   
      stock-based compensation expense
    		3,556,000 3,478,000 3,585,000 3,131,000 3,101,000 2,673,000 2,918,000 3,024,000 1,578,000 935,000 
      change in fair value of mskcc success payments liability
    		1,683,000 139,000 -279,000 -255,000 -1,388,000 1,607,000 -1,052,000 -1,596,000 -2,158,000  
      acquired in-process research and development
    		    300,000 0   0 0 
      accretion of discounts on investments in marketable securities
    		          
      non-cash lease expense
    		497,000 527,000 509,000 515,000 397,000 622,000 500,000 500,000   
      changes in operating assets and liabilities:
    		          
      accounts receivable
    		985,000 -367,000 767,000 -1,331,000 195,000 127,000 -150,000 779,000 -575,000 -576,000 
      contract assets
    		234,000 -177,000 158,000 607,000 -348,000 195,000 -600,000 -6,000 365,000 -1,023,000 
      other receivables
    		59,000 -850,000 175,000 545,000 485,000 395,000 1,075,000 1,313,000 -127,000 2,221,000 
      prepaid expenses and other current assets
    		914,000 -1,504,000 545,000 1,811,000 638,000 -1,266,000 949,000 -1,296,000 -1,284,000 -917,000 
      other assets
    		-18,000 -149,000 57,000 62,000 -203,000 -35,000 161,000 -487,000 -165,000 0 
      accounts payable
    		730,000 -953,000 540,000 1,502,000 -153,000 989,000 -1,642,000 -1,915,000 291,000 -183,000 
      accrued expenses and other current liabilities
    		2,895,000 3,279,000 3,707,000 -4,138,000 1,044,000 -208,000 3,948,000 -2,831,000 -574,000 3,846,000 
      deferred revenue, current and long-term
    		-606,000 -21,568,000 6,328,000 -1,097,000 -1,567,000 -807,000 -1,898,000 -572,000 -1,032,000 -1,122,000 
      operating lease liabilities
    		-346,000 220,000 -188,000 -323,000 -124,000 -97,000 -97,000 -85,000   
      other liabilities
    		    0 0 -7,000 -8,000 -140,000 -8,000 
      deferred tax liabilities
    		          
      net cash from operating activities
    		-21,379,000 -28,788,000 -15,185,000 -27,939,000 -25,044,000 -22,376,000 -21,873,000 -21,673,000 -21,389,000 -14,967,000 
      capex
    		-2,141,000 -6,758,000 -1,705,000 -317,000 -1,757,000 -1,304,000 -2,620,000 -723,000 -685,000 -930,000 
      free cash flows
    		-23,520,000 -35,546,000 -16,890,000 -28,256,000 -26,801,000 -23,680,000 -24,493,000 -22,396,000 -22,074,000 -15,897,000 
      cash flows from investing activities:
    		          
      proceeds from sales and maturities of marketable securities
    		54,995,000 112,168,000 72,360,000 98,665,000       
      purchases of marketable securities
    		-84,192,000 -175,892,000 -58,743,000 -75,931,000 -86,511,000 -70,806,000 -71,062,000 -110,684,000   
      purchases of property and equipment
    		-2,277,000 -4,752,000 -2,553,000 -2,031,000 -1,757,000 -1,354,000 -2,620,000 -723,000 -685,000 -930,000 
      payments to acquire in-process research and development
    		    -300,000    0  
      net cash from investing activities
    		-31,474,000 -68,476,000 11,064,000 20,703,000 1,170,000 -8,339,000 -13,973,000 -72,107,000 -173,961,000 -1,930,000 
      cash flows from financing activities:
    		          
      proceeds from public follow-on public offering, net of offering expenses
    		          
      proceeds from issuance of common stock in a private placement with pfizer
    		0 -160,000         
      proceeds from exercise of stock options and purchases of common stock under employee stock purchase plan
    		70,000 753,000 236,000 519,000 127,000 654,000 362,000 990,000   
      proceeds from issuance of common stock related to at-the-market offering, net of offering expenses
    		0 -1,000 -115,000 1,123,000       
      net cash from financing activities
    		-43,000 135,128,000 17,571,000 1,642,000 127,000 654,000 362,000 990,000 460,000 322,683,000 
      net decrease in cash, cash equivalents, and restricted cash
    		   -5,594,000       
      cash, cash equivalents, and restricted cash — beginning of period
    		0 0 0 58,384,000 0 46,000 -46,000 240,466,000 0 0 
      cash, cash equivalents, and restricted cash — end of period
    		-52,896,000 37,864,000 13,450,000 52,790,000 -23,747,000 -30,015,000 -35,530,000 147,676,000 -194,890,000 305,786,000 
      reconciliation of cash, cash equivalents, and restricted cash
    		          
      cash and cash equivalents
    		-52,896,000 37,864,000 13,450,000 52,744,000 -23,747,000 -30,061,000 -35,484,000 147,630,000 -194,890,000 305,786,000 
      restricted cash
    		0 0 0 46,000 0 0 0 46,000 0 0 
      cash, cash equivalents, and restricted cash on the balance sheet
    		       147,676,000 -194,890,000 305,786,000 
      supplemental cash flow information:
    		          
      cash paid for income taxes
    		0 0       0 0 
      supplemental schedule of non-cash investing and financing activities:
    		          
      purchases of property and equipment included in accounts payable and accrued expenses
    		136,000 -2,006,000 848,000 1,714,000       
      right-of-use-assets obtained in exchange for new operating lease liabilities
    		    0 0     
      (accretion of discounts) and amortization of premiums on investments
    		 -2,444,000         
      proceeds from follow-on public offering, net of offering expenses
    		          
      net increase in cash, cash equivalents, and restricted cash
    		 37,864,000   -23,747,000 -30,061,000 -35,484,000 -92,790,000 -194,890,000 305,786,000 
      total cash, cash equivalents, and restricted cash
    		 37,864,000 13,450,000 52,790,000  -30,061,000     
      offering costs included in accrued expenses
    		 -47,000 44,000 116,000       
      acquired in-process research and development accrued
    		          
      amortization of investment premiums
    		   -1,494,000  -343,000 122,000 327,000   
      loss on disposal of property and equipment
    		          
      extinguishment of ppp loan and accrued interest
    		          
      amortization of premiums on marketable securities
    		          
      deferred rent and lease incentive liability
    		        264,000 171,000 
      maturities of marketable securities
    		    89,738,000 64,121,000 59,709,000 39,300,000   
      proceeds from initial public offering of common stock, net of offering costs
    		        0  
      proceeds from issuance of series c convertible preferred stock, net of issuance costs
    		        0  
      repayment of promissory note
    		        0 0 
      payments on capital lease
    		        0  
      purchases of property and equipment unpaid at period end
    		          
      conversion of convertible preferred stock to common stock at closing of initial public offering
    		        0  
      loss on disposal of fixed assets
    		         0 
      extinguishment of ppp loan
    		         0 
      acquisition of property and equipment included in accrued expenses and other current liabilities
    		     50,000     
      payment of deferred issuance costs
    		          
      deferred issuance costs related to initial public offering unpaid at period end
    		          
      interest expense
    		          
      initial fair value of mskcc success payments liability
    		          
      proceeds from sale of equity securities
    		          
      proceeds from sale of property and equipment
    		          
      proceeds from exercise of stock options
    		        460,000  
      proceeds from ppp loan
    		          
      capital lease financing for purchase of assets
    		          
      issuance of common stock to acquire in-process research and development
    		          
      non-cash consideration in exchange for licensing and collaboration revenue
    		          
      change in fair value of success payments liability
    		          
      payments to acquire in-process research & development
    		          
      issuance of series c convertible preferred stock
    		          
      proceeds from common stock options exercised
    		          
      principal payments for capital lease
    		          
      purchases of property and equipment accrued
    		          
      deferred issuance costs related to initial public offering accrued
    		          
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.